---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-037255"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:35:20.274632+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Fennec licenses PEDMARQSI to Norgine for EU/AU/NZ; €40M upfront, up to €210M milestones

## Summary
- Exclusive license covers Europe (incl. UK), Australia, New Zealand; Norgine to commercialize.
- Fennec receives €40M upfront paid March 15, 2024, plus up to €210M in regulatory/commercial milestones.
- Tiered royalties on net sales range from mid-teens to mid-twenties percent.
- PEDMARQSI is first EU/U.K.-approved therapy to reduce cisplatin-induced hearing loss in pediatric patients.
- Estimated >5,000 pediatric patients/year eligible in Europe; approvals based on Phase 3 trials showing ~50% hearing loss reduction.

## SEC filing metadata
- accession: 0001104659-24-037255
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465924037255/0001104659-24-037255-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465924037255/tm249428d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-037255
- JSON: https://secwatch.observer/filing/0001104659-24-037255.json
- Plain text: https://secwatch.observer/filing/0001104659-24-037255.txt

## Key facts
- Material Agreements
  FENNEC PHARMACEUTICALS INC. entered into License and Supply Agreement with Norgine Pharma UK Limited valued at €40 million (effective 2024-03-15).
  - Action: entry
  - Agreement: license
  - Counterparty: Norgine Pharma UK Limited
  - Value: €40 million
  - Effective: 2024-03-15
  source text: On March 15, 2024, Fennec Pharmaceuticals, Inc., a Delaware corporation (“Fennec”) and wholly owned subsidiary of Fennec Pharmaceuticals Inc. (the “Company”), entered into a License and Supply Agreement (the “Agreement”) with Norgine Pharma UK Limited (“Norgine”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465924037255/0001104659-24-037255-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.